Synaptogenix (NASDAQ:TAOX) Shares Down 3.4% – Here’s What Happened

Shares of Synaptogenix, Inc. (NASDAQ:TAOX) traded down 3.4% during trading on Tuesday . The stock traded as low as $3.56 and last traded at $3.72. 68,949 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 142,797 shares. The stock had previously closed at $3.85.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Synaptogenix from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Synaptogenix currently has a consensus rating of “Sell”.

Synaptogenix Stock Down 3.4%

The stock has a 50-day moving average of $4.99 and a 200 day moving average of $5.03. The company has a market capitalization of $27.79 million, a PE ratio of -0.28 and a beta of 1.41.

Synaptogenix (NASDAQ:TAOX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.43 earnings per share (EPS) for the quarter. The company had revenue of $5.96 million for the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.